PR Newswire PharmaOriginal article
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
Phase 3IBI363/TAK-928Positive
AI Analysis
Summary
Innovent Biologics announced an expansion of its global Phase 3 MarsLight-11 study of IBI363/TAK-928 in immunotherapy-resistant NSCLC to include patients with non-squamous NSCLC histology.
Clinical Trial Data
Phase
3
Outcome Details
Study expansion announced to include non-squamous NSCLC patients
Importance:5/10
Sentiment:
0.30
Phase 3 trialoncologyNSCLCbispecificimmunotherapyexpansion
Read the original article
Published by PR Newswire Pharma on September 28, 2026 12:00 AM